Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...

Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

The patient, diagnosed with a large hepatocellular carcinoma in the right lobe of the liver, faced significant challenges due ...

Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had ...

Hepatitis delta virus testing in those with chronic hepatitis B is low, and improvements are needed to reduce long-term, ...

Hepion Pharmaceuticals ( (HEPA) ) just unveiled an announcement.

—Sobia Laique, MD, of Cleveland Clinic, discusses the multitude of pathways that contribute to hepatocarcinogenesis in MASH, including metabolic derangement, gut microbiota, and more. (3:06 ...

A research result was announced that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...